Bayer has led a Series A funding round in Robigo, a startup developing a crop protection platform that Dealroom's coverage sizes against a $10 billion market opportunity.

The round, surfaced through Dealroom's deal-tracking database, marks another move by one of the Big Four agriscience companies into early-stage biological and next-generation crop protection technology. Bayer — already the maker of the Corteva-competing Deciphera and Dekalb seed brands and the owner of Crop Science division revenues that topped €25 billion in recent fiscal years — did not disclose the round's size or valuation in the Dealroom entry.

Robigo is building what the report describes as a platform aimed at the $10 billion crop protection segment. The figure positions the startup in the fastest-growing slice of the global plant-protection market, where biological products have been gaining share against conventional chemistry as regulatory pressure tightens on synthetic actives in both the European Union and the United States.

For growers, the deal signals where input-supply capital is flowing. When Bayer, Syngenta, BASF and Corteva place early-stage bets, distribution follows: new modes of action typically reach cooperative shelves and retailer racks through the majors' existing channels within two to three seasons of commercialization. That trajectory matters for row-crop budgets, where crop protection spending has run between $60 and $80 per acre on corn and soybean operations, according to university extension cost estimates.

The investment also comes as resistance management pushes demand for novel actives. Weed, insect and disease populations resistant to established chemistries continue to erode efficacy on millions of acres, and integrated pest management programs increasingly call for rotating or combining biological modes of action with synthetic ones.

Dealroom's listing did not specify the funding amount, the participation of other investors, or a timeline for product commercialization. Bayer has not issued a separate press release detailing the transaction as of the report's publication.

The round fits a broader pattern. Bayer's investment arm has backed multiple agtech startups in recent years, and the company has stated publicly that biologicals represent a strategic growth pillar alongside its seed-and-trait and conventional chemistry portfolios.

Watch for Robigo's platform to move from laboratory to field trials, the step that will determine whether the $10 billion market framing translates into products growers can price into their input budgets.